Cargando…

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A

The treatment of inflammatory bowel diseases (IBD) can be challenging, especially in elderly multimorbid patients. Since incidence and prevalence rates of IBD are rising steadily, treatment of older patients with relevant and also rare comorbidities will be of increasing relevancy for caregivers. He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schäffler, Holger, Huth, Astrid, Lamprecht, Georg, Anders, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875292/ https://www.ncbi.nlm.nih.gov/pubmed/29606934 http://dx.doi.org/10.1159/000485372

Ejemplares similares

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
por: Trieu, Judy A., et al.
Publicado: (2017)

Development and Improvement of Simple Colonic Mucosal Ulcer during Treatment of Severe Ulcerative Colitis with Tacrolimus
por: Ito, Ayumi, et al.
Publicado: (2017)

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
por: Ben-Horin, Shomron, et al.
Publicado: (2022)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

A Patient with Ulcerative Colitis Complicated by Systemic Vein Thrombosis
por: Meštrović, Antonio, et al.
Publicado: (2018)

Severe de novo Ulcerative Colitis following Ixekizumab Therapy
por: Philipose, Jobin, et al.
Publicado: (2018)

Hypereosinophilic Syndrome Secondary to Ulcerative Colitis and Primary Sclerosing Cholangitis
por: Ramos, Davi Viana, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
por: Hoffmann, Sebastian, et al.
Publicado: (2018)

Hemophilia A Complicated by Ulcerative Colitis
por: Olivier, Maxim, et al.
Publicado: (2018)

Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
por: Terui, Hitoshi, et al.
Publicado: (2023)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

New and emerging treatments for ulcerative colitis: a focus on vedolizumab
por: Gledhill, Tamsin, et al.
Publicado: (2013)

Clinical and Pathologic Remission of Pediatric Ulcerative Colitis with Serum-Derived Bovine Immunoglobulin Added to the Standard Treatment Regimen
por: Soriano, Rachelle A., et al.
Publicado: (2017)

Febrile Neutropenia with Thrombocytopenia after Infliximab Induction in a Patient with Ulcerative Colitis
por: Gomez, Gustavo, et al.
Publicado: (2016)

Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
por: Hirsch, Ayal, et al.
Publicado: (2015)

Sarcoidosis of the Intra- and Extrahepatic Bile Ducts with Concomitant Cholangitis in a Patient with Ulcerative Colitis
por: Jebran, Ahmad Fasel, et al.
Publicado: (2019)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Colonic Dilatation Complicating Acute Severe Ulcerative Colitis Managed Successfully with Accelerated Infliximab Dosing
por: Bui, Hoang Huu, et al.
Publicado: (2023)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Elevated Lipase during Initial Presentation of Ulcerative Colitis in a Pediatric Patient: Do We Check for It
por: Ray, Piyali, et al.
Publicado: (2016)

Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis
por: Singh, Amrinder, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Ulcerative Colitis in Hemophilia A Patient: Case Report
por: Yusuf, Fauzi, et al.
Publicado: (2021)

Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine
por: Philippou, Alicia, et al.
Publicado: (2021)

Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
por: Nakamura, Masanao, et al.
Publicado: (2020)

Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report
por: Zhang, Jie, et al.
Publicado: (2022)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
por: Oki, Yusuke, et al.
Publicado: (2023)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
por: Dart, Robin J, et al.
Publicado: (2017)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis
por: Gonzalez-Vivo, Maria, et al.
Publicado: (2022)

Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy
por: Takatsu, Noritaka, et al.
Publicado: (2020)

Successful Montelukast Treatment in an Infant with Steroid-Resistant Eosinophilic Colitis
por: Wang, Nai-Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6lc2g68tb5mi81ujc94huv9eil